A3P Biomedical
A3P Biomedical is a Swedish diagnostics company that develops and commercializes Stockholm3, a blood-based multi-biomarker test for early detection of aggressive prostate cancer. The company serves hospitals, urology clinics, and regional screening programs across Europe and the United States through laboratory partner channels.
- Company typePrivate
- Founded2020
- HeadquartersStockholm, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What A3P Biomedical does
A3P Biomedical is a Swedish diagnostics company headquartered in Stockholm that develops and commercializes Stockholm3, a blood-based multi-biomarker test designed for the early detection of aggressive prostate cancer. The test combines protein biomarkers, a polygenic risk score, and clinical data in a proprietary algorithm — developed at Karolinska Institutet — to identify clinically significant prostate cancer while reducing unnecessary biopsies compared to standard PSA screening. The product has been validated across multiple prospective screening trials involving more than 90,000 men in Europe and is supported by inclusion in NCCN, AUA, and Swedish national clinical guidelines, as well as a UK NICE Medtech Innovation Briefing.
The company serves hospitals, urology clinics, and regional and national prostate cancer screening programs across Sweden, Norway, Finland, Switzerland, Germany, the United Kingdom, and, since July 2024, the United States. It monetizes Stockholm3 primarily through laboratory-developed test (LDT) partnerships with established diagnostic channels — Unilabs in Europe and BioAgilytix in the U.S., alongside a November 2024 partnership with labor team in Switzerland — and through direct relationships with named health systems including Stavanger University Hospital, Capio St Görans, Zürich University Hospital, Groves Medical, Martini Klinik, and Mehiläinen, as well as Swedish regional programs (Region Stockholm, Region Värmland).
A3P operates a laboratory in Uppsala, is organized with 11–50 employees, and is led by an interim CEO following the May 2024 departure of David Rosén. The company is investing in U.S. commercialization, pursuing FDA approval, executing a multi-ethnic screening trial (SEPTA) to broaden the validated population, and has hired a VP Marketing & Sales and CFO. Funding to date includes approximately SEK 510M raised across rounds, led by a SEK 400M private placement in May 2022. The business is at an early commercial stage with undisclosed revenue.
A3P Biomedical firmographics
Firmographics- Name
- A3P Biomedical
- Legal name
- A3P Biomedical AB (publ)
- Website
- https://a3p.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- A3P Biomedical is a Swedish diagnostics company that develops and commercializes Stockholm3, a blood-based multi-biomarker test for early detection of aggressive prostate cancer. The company serves hospitals, urology clinics, and regional screening programs across Europe and the United States through laboratory partner channels.
- Ownership category
- akta.pro rank
A3P Biomedical industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where A3P Biomedical is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
A3P Biomedical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Revenue model
- Diagnostic Testing Services: A3P Biomedical generates revenue through its proprietary Stockholm3 blood test for early detection of aggressive prostate cancer. The test is provided as a Laboratory Developed Test (LDT) through partnerships and directly to healthcare providers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Laboratory Developed Test (LDT) pricing through healthcare providers |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
A3P Biomedical product offering
Product offeringCore offering
A3P Biomedical develops and commercializes Stockholm3, a proprietary blood-based diagnostic test for early detection and risk stratification of aggressive prostate cancer. The test combines protein biomarkers, a polygenetic risk score, and clinical variables through a proprietary multi-biomarker algorithm to predict the probability of clinically significant prostate cancer at biopsy. It is offered as a Laboratory Developed Test (LDT) through laboratory channel partners and direct hospital relationships across Europe and the United States.
Product overview
A3P Biomedical offers a single unified product, Stockholm3, which is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. Stockholm3 runs a combination of protein biomarkers, genetic biomarkers, and clinical information through a proprietary algorithm to generate a probability score for clinically significant cancer at biopsy. The company operates primarily through laboratory partnerships (BioAgilytix in the USA, labor team in Switzerland, Unilabs in Sweden) for sample logistics and analysis, with its Uppsala, Sweden laboratory performing core analysis. A3P Biomedical also operates A3P Lab AB as a registered healthcare provider subsidiary.
Differentiator
Problem solved
Functional benefit
Brands
- Stockholm3: A clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer, combining protein biomarkers, genetic biomarkers, and clinical information through an algorithm
Products and services
- Stockholm3 Proprietary blood-based diagnostic test that combines protein biomarkers, a polygenetic risk score, and clinical variables through a multi-biomarker algorithm to predict the probability of clinically significant (Grade Group ≥2) prostate cancer at biopsy. Used as a reflex test after elevated PSA (1.5–20 ng/ml) or as a first-line screening tool. Available as a Laboratory Developed Test (LDT) through BioAgilytix (USA), Unilabs (Sweden), labor team (Switzerland), and direct hospital relationships across Europe.
Quantifiable outcome
- Detects 90% of aggressive prostate cancers vs 74% for PSA at ≥3 ng/ml
- +5 more outcomes
Companies that use A3P Biomedical
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles3 records
A3P Biomedical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
A3P Biomedical partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- labor teamcoreStrategic partnership with labor team, a Swiss laboratory based in Goldach, makes Stockholm3 available throughout Switzerland. labor team handles all logistics and wet lab analysis for Stockholm3 in Switzerland.
- BioAgilytixcoreA3P Biomedical and BioAgilytix entered partnership to introduce Stockholm3 as a Lab Developed Test (LDT) in the US market. BioAgilytix provides CLIA-certified laboratory services from Durham, NC. Stockholm3 became commercially available in the USA through BioAgilytix in July 2024.
- UnilabscoreUnilabs partnership for Stockholm3 in Sweden enables healthcare providers to order Stockholm3 through Unilabs' Labportalen portal. Sampling at Unilabs laboratories or care provider facilities, with analysis by A3P Biomedical.
- Zürich University HospitalcoreFirst clinic in Switzerland to use Stockholm3 for prostate cancer testing in men aged 45-75. Blood samples analyzed at A3P's Uppsala lab. Men with elevated risk offered MRI examination.
- Martini KlinikcoreWorld-renowned prostate cancer center in Hamburg, Germany independently validated Stockholm3. Validation study showed 52% reduction of unnecessary biopsies while detecting 92% of Grade Group ≥2 prostate cancers.
- Scientific Advisory BoardcoreA3P formed Scientific Advisory Board chaired by Prof. Per-Anders Abrahamsson (former EAU Secretary General) with members including Prof. Alberto Briganti, Prof. Markus Graefen, Prof. Henrik Grönberg, and Assoc. Prof. Jochen Walz.
Scale indicators8 records
Recent moves12 records
Expansion highlights6 records
A3P Biomedical competitors and assessment
Company assessmentBroad incumbents
- Guardant Health: Guardant Health is a liquid biopsy leader in oncology with proprietary blood-based ctDNA technology; its scale, R&D investment, and presence in urology through Shield could enable entry into prostate cancer screening, posing a long-term competitive threat.
- Natera: Natera offers Signatera, a tumor-informed ctDNA MRD test, and has capabilities in blood-based oncology diagnostics that could be applied to prostate cancer screening, representing a broader blood-based cancer diagnostics incumbent.
- Siemens Healthineers: Siemens Healthineers is a broad diagnostics and imaging incumbent whose ADVIA Centaur and Atellica immunoassay platforms and urology partnerships could enable entry into prostate cancer blood-based screening at scale.
- Exact Sciences: Exact Sciences is a leading cancer diagnostics company (Cologuard, Oncotype DX) with established US sales infrastructure and payor relationships that it could leverage if it entered prostate cancer screening, representing a broad incumbent threat in the oncology diagnostics space.
- Philips (IntelliSpace Prostate): Philips offers IntelliSpace Prostate, an AI-based prostate cancer detection and reporting solution integrated with MRI workflows, competing in the broader prostate cancer diagnostic pathway where Stockholm3 is positioned as a triage/reflex test.
Direct peers
- MDxHealth: MDxHealth offers SelectMDx and ConfirmMDx, urine- and tissue-based prostate cancer diagnostic tests that similarly aim to reduce unnecessary biopsies and identify aggressive prostate cancer, directly competing with Stockholm3 in the urology biomarker space.
- OPKO Health (4Kscore): OPKO Health's 4Kscore test is a blood-based kallikrein panel for prostate cancer risk assessment, directly competing with Stockholm3 as a pre-biopsy blood test for men with elevated PSA in the same customer segment.
- Myriad Genetics: Myriad offers Prolaris, a tissue-based genetic test for prostate cancer aggressiveness assessment, competing with Stockholm3 in risk stratification for prostate cancer patients, particularly in post-biopsy decision-making.
Emerging players
- Epigenomics: Epigenomics develops blood-based cancer screening tests including colorectal screening (Epi proColon), with research capabilities in DNA methylation biomarkers that could be extended toward prostate cancer applications, representing an emerging molecular diagnostics peer.
Others
- Bio-Techne: Bio-Techne provides protein biomarker reagents and analytical tools (including Simple Western and Ella platforms) used in biomarker assay development; comparable as an enabling tools provider in the same biomarker diagnostics ecosystem as Stockholm3.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
A3P Biomedical social profiles
Digital presenceA3P Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
A3P Biomedical leadership team
Management profileNumber of profiles
Profiles7 records
A3P Biomedical subsidiaries and ownership
Company hierarchySubsidiaries2 records
A3P Biomedical funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
A3P Biomedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about A3P Biomedical
What does A3P Biomedical do?
A3P Biomedical develops and commercializes Stockholm3, a proprietary blood-based diagnostic test for early detection and risk stratification of aggressive prostate cancer. The test combines protein biomarkers, a polygenetic risk score, and clinical variables through a proprietary multi-biomarker algorithm to predict the probability of clinically significant prostate cancer at biopsy. It is offered as a Laboratory Developed Test (LDT) through laboratory channel partners and direct hospital relationships across Europe and the United States.
Is A3P Biomedical a public or private company?
A3P Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.
When was A3P Biomedical founded?
A3P Biomedical was founded in 2020. It employs 11 to 50 people.
Where is A3P Biomedical based?
A3P Biomedical is headquartered in Stockholm, Sweden, in the Europe region.
How does A3P Biomedical make money?
One revenue line is on record: diagnostic Testing Services.
Who are A3P Biomedical's main competitors?
Broad incumbents on record are Guardant Health, Natera, Siemens Healthineers, Exact Sciences and Philips (IntelliSpace Prostate). Direct peers are MDxHealth, OPKO Health (4Kscore) and Myriad Genetics. Epigenomics is listed as an emerging player. Bio-Techne is listed as an others.
Does A3P Biomedical have an API?
No public API is recorded for A3P Biomedical.
What industry is A3P Biomedical in?
A3P Biomedical's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAF, Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk). Its NAICS code is 621511 and its SIC code is 8071.